

[FR Doc. 04-8443 Filed 4-14-04; 8:45 am]

BILLING CODE 4160-01-C

DEPARTMENT OF HEALTH AND HUMAN SERVICES**National Institutes of Health****Government-Owned Inventions; Availability for Licensing****AGENCY:** National Institutes of Health, Public Health Service, DHHS.**ACTION:** Notice.

SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

Therapeutic Administration of the Scrambled Anti-Angiogenic Peptide C16Y

K.E. Csaky (NEI), M.L. Ponce (NEI), H. Kleinman (NIDCR)
PCT Application No. PCT/US04/04142 filed 12 Feb 2004 (DHHS Reference No. E-008-2004/0-PCT-01)
Licensing Contact: Susan Rucker; 301/435-4478; *ruckersu@mail.nih.gov*.

This application relates to the field of anti-angiogenesis. In particular, the application describes and claims compositions and methods useful for treating diseases associated with angiogenesis such as macular degeneration (AMD), diabetic retinopathy, neovascular glaucoma and cancers associated with solid tumors particularly, breast cancer. The compositions and methods offer alternatives to other ocular anti-angiogenic agents currently in development due to their ease of manufacture and mode of action on an integrin pathway.

The compositions and methods utilize a synthetic peptide of between 8 and 12

amino acid residues derived from a region of the $\gamma 1$ chain of laminin-1 that binds to endothelial cell integrins $\alpha v \beta 3$ and $\alpha 5 \beta 1$. The preferred embodiment, designated C16Y, is 12 amino acids in length and is easily prepared by conventional peptide synthesis. The anti-angiogenic properties of the C16Y peptide have been demonstrated in an *in vitro* model of choroidal neovascularization and in tumor-bearing mice.

This work has been published, in part at ML Ponce et al., *Cancer Research* 63(16): 5060 (Aug 15, 2003).

Hybrid Adeno-Retroviral Vector for the Transformation of Cells

Changyu Zheng, Brian C. O'Connell, Bruce J. Baum (NIDCR)

U.S. Provisional Application No. 60/179,327 filed 31 Jan 2000 (DHHS Reference No. E-258-1998/0-US-01); PCT Application No. PCT/US01/03026 filed 30 Jan 2001 (DHHS Reference No. E-258-1998/0-PCT-02); U.S. Patent Application No. 10/182,644 filed 30 Jul 2002 (DHHS Reference No. E-258-1998/0-US-03)

Licensing Contact: Jesse Kindra; 301/435-5559; *kindraj@mail.nih.gov*.

The invention described and claimed in this patent application provides for novel hybrid vectors which may be used for cell transformation, either *in vivo* or *in vitro*. The hybrid vectors have an adenoviral backbone with retroviral long terminal repeats (LTRs). Such vectors are capable of transforming dividing or non-dividing cells and integrate stably into the chromosome providing a means of efficient, reliable, long-term gene expression. The vector was packaged as a recombinant adenovirus and delivered to the target cell. Unlike other chimeric or hybrid vector systems, only a single vector is required to deliver a transgene of interest, and retroviral structural proteins are not required.

This work has been published, in part, in: Zheng *et al.*, *Nature Biotechnol.* (2000 Feb) 18(2):176-180; Zheng *et al.*, *Biochem. Biophys. Res. Commun.* (2002 Feb 15) 291(1):34-40; Zheng *et al.*, *Biochem. Biophys. Res. Commun.* (2003 Jan 3) 300(1):115-20; Zheng *et al.*, *Virology* (2003 Sep 1) 313(2):460-72.

Antitumor Macrocyclic Lactones

Michael R. Boyd (NCI)

U.S. Patent No. 6,353,019 issued 05 Mar 2002 (DHHS Reference No. E-244-1997/0-US-07) and related foreign patent applications; and

Vacuolar-Type (H+)-ATPase-Inhibiting Compounds and Uses Thereof

Michael R. Boyd (NCI)

U.S. Patent Application No. 09/914,708 filed 31 Aug 2001 (DHHS Reference No. E-244-1997/3-US-06) and related foreign patent applications
Licensing Contact: George Pipia; 301/435-5560; *pipia@mail.nih.gov*.

This technology covers a broad composition of matter which includes the salicylhalalamides, lobatamides, and numerous other structurally related small molecules which have been shown to inhibit mammalian vacuolar ATPase at low nanomolar concentrations. The compounds are also potent inhibitors of cancer cell growth, with particular specificity for melanoma, osteosarcoma and selected lung, colon and CNS tumor cell lines. Experimental tumor and pharmacokinetic studies are underway to select the most effective analogs for further development. The potential of these compounds to inhibit invasion and metastasis to bone sites is also under investigation.

Dated: April 7, 2004.

Steven M. Ferguson,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 04-8493 Filed 4-14-04; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES**National Institutes of Health****Notice of Meeting; Interagency Autism Coordinating Committee**

The National Institutes of Health (NIH) hereby announces a meeting of the Interagency Autism Coordinating Committee (IACC) to be held on May 11, 2004, on the NIH campus in Bethesda, Maryland.

The Children's Health Act of 2000 (Pub. L. 106-310), Title I, Section 104, mandated the establishment of an Interagency Autism Coordinating Committee (IACC) to coordinate autism research and other efforts within the Department of Health and Human Services (DHHS). In April 2001, Secretary Tommy Thompson delegated the authority to establish the IACC to the NIH. The National Institute of Mental Health (NIMH) at the NIH has been designated the lead for this activity.

The IACC meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such

as sign language interpretation or other reasonable accommodations, should notify the contact person listed below in advance of the meeting.

Name of Committee: Interagency Autism Coordinating Committee.

Date: May 11, 2004.

Time: 9 a.m.–4:30 p.m.

Agenda: Discussion of autism activities across Federal agencies.

Place: National Institutes of Health, Building 31, Conference Room 10 (6th floor), 31 Center Drive, Bethesda, Maryland 20892.

Contact Person: Ann Wagner, Ph.D., Division of Services and Intervention Research, National Institute of Mental Health, NIH, 6001 Executive Boulevard, Room 7142, MSC 9633, Bethesda, Maryland 20892, e-mail: awagner@mail.nih.gov, Phone: (301) 443-4283.

Any member of the public interested in presenting oral comments to the committee may notify the contact person listed on this notice at least 5 days in advance of the meeting. Interested individuals and representatives of organizations may submit a letter of intent, a brief description of the organization represented, and a short description of the oral presentation. Presentations may be limited to 5 minutes; both printed and electronic copies are requested for the record. In addition, any interested person may file written comments with the committee by forwarding his/her statement to the contact person listed on this notice. The statement should include the name, address, telephone number and, when applicable, the business or professional affiliation of the interested person.

Information about the meeting and registration forms are also available on-line on the NIMH homepage at <http://www.nimh.nih.gov/autismiacc/index.cfm>.

Dated: April 7, 2004.

Raynard S. Kington,

Deputy Director, National Institutes of Health.

[FR Doc. 04-8494 Filed 4-14-04; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

President's Council on Physical Fitness and Sports

AGENCY: Office of the Secretary, Office of Public Health and Science, HHS.

ACTION: Notice of meeting.

SUMMARY: As stipulated by the Federal Advisory Committee Act, the Department of Health and Human

Services (DHHS) is hereby giving notice that the President's Council on Physical Fitness and Sports will hold a meeting. This meeting is open to the public. A description of the Council's functions is included also with this notice.

DATES: May 5, 2004, from 8:30 a.m. to 4 p.m.

ADDRESSES: Department of Health and Human Services, Hubert H. Humphrey Building, Room 800, 200 Independence Avenue, SW., Washington, DC 20201.

FOR FURTHER INFORMATION CONTACT: Melissa Johnson, Executive Director, President's Council on Physical Fitness and Sports, Hubert H. Humphrey Building, Room 738H, 200 Independence Avenue, SW., Washington, DC 20201, (202) 690-5187.

SUPPLEMENTARY INFORMATION: The President's Council on Physical Fitness and Sports (PCPFS) was established originally by Executive Order 10673, dated July 16, 1956. PCPFS was established by President Eisenhower after published reports indicated that American boys and girls were unfit compared to the children of Western Europe. Authorization to continue Council operations was given at appropriate intervals by subsequent Executive Orders. The Council has undergone two name changes and several reorganizations. Presently, the PCPFS is a program office located organizationally in the Office of Public Health and Science within the Office of the Secretary in the U.S. Department of Health and Human Services.

On June 6, 2002, President Bush signed Executive Order 13256 to reestablish the PCPFS. Executive Order 13256 was established to expand the focus of the Council. This directive instructed the Secretary to develop and coordinate a national program to enhance physical activity and sports participation. The Council currently operates under the stipulations of the new directive. The primary functions of the Council include: (1) To advise the President, through the Secretary, on the progress made in carrying out the provisions of the enacted directive and recommend actions to accelerate progress; (2) to advise the Secretary on ways and means to enhance opportunities for participation in physical fitness and sports, and, where possible, to promote and assist in the facilitation and/or implementation of such measures; (3) to advise the Secretary regarding opportunities to extend and improve physical activity/fitness and sports programs and services at the national, state and local levels; and (4) to monitor the need for the enhancement of programs and

educational and promotional materials sponsored, overseen, or disseminated by the Council and advise the Secretary, as necessary, concerning such needs.

The PCPFS holds at a minimum, one meeting in the calendar year to (1) Assess ongoing Council activities and (2) discuss and plan future projects and programs.

Dated: April 9, 2004.

Melissa Johnson,

Executive Director, President's Council on Physical Fitness and Sports.

[FR Doc. 04-8595 Filed 4-14-04; 8:45 am]

BILLING CODE 4150-35-U

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Environmental Health Sciences; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Advisory Environmental Health Sciences Council.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Advisory Environmental Health Sciences Council.

Date: May 17, 2004.

Open: 8:30 a.m. to 2 p.m.

Agenda: Discussion of program policies and issues.

Place: Sheraton Imperial Hotel and Convention Center, 4700 Emperor Boulevard, The Empire Room (DE), Durham, NC 27703.

Closed: 2 p.m. to Adjournment.

Agenda: To review and evaluate grant applications.

Place: Sheraton Imperial Hotel and Convention Center, 4700 Emperor Boulevard, The Empire Room (DE), Durham, NC 27703.

Contact Person: Anne P. Sassman, PhD, Director, Division of Extramural Research